Beyond Food Cravings: Exploring the Potential of GLP-1²

Short answer

GLP-1 medications like semaglutide and tirzepatide are being studied for their potential effects beyond weight management, including how they may influence cravings and the brain's reward system. Early research suggests possible connections to alcohol cravings and other compulsive behaviors, but more studies are needed. Learn how GLP-1² combines semaglutide and tirzepatide and what current research says about the relationship between GLP-1 medications, cravings, and addictive behaviors.

DrWell programs use compounded medications, which are not FDA approved. Talk with your provider about whether a program is right for you.

Medically reviewed/Jonathan Kaplan, MD, MPH/November 16, 2026/3
Beyond Food Cravings: Exploring the Potential of GLP-1²
Up nextNext article title placeholderFind a provider

How Do GLP-1s Affect Cravings?

GLP-1 medications mimic naturally occurring hormones involved in appetite and blood sugar regulation. However, GLP-1 receptors are also found in areas of the brain involved in motivation, reward, and decision-making.

These brain pathways help explain why certain experiences, such as eating, drinking alcohol, gambling, or shopping, can trigger powerful urges. Researchers believe GLP-1 medications may influence these reward pathways, potentially affecting the desire to repeat certain behaviors.

In other words, their effects may extend beyond feeling full after a meal.

What Is GLP-1²?

The idea behind GLP-1² is that semaglutide and tirzepatide may work together to reduce alcohol cravings. In lab studies, semaglutide binds more tightly than tirzepatide to the GLP-1 receptor, and in mice it blunted the surge in dopamine, a chemical involved in the brain’s reward response, after alcohol exposure. In lab studies, tirzepatide leaves more GLP-1 receptors on the cell surface, where they remain available to respond. The hope is that combining these effects could help curb cravings and sustain that benefit over time, a concept called chronic sensitization.

DrWell is working with the FDA right now to evaluate the clinical effectiveness of GLP-1² in human clinical trials for the treatment of alcohol use disorder. However, the combination medication is available off-label and legally right now because both individual medications are FDA approved!

What Does the Research Say?

Scientists are investigating potential connections between GLP-1 medications and several addictive or compulsive behaviors:

  • Alcohol: Early human studies involving semaglutide have found reductions in alcohol cravings and certain measures of consumption. This is one of the more developed areas of research, with promising findings encouraging further investigation into how GLP-1s may influence alcohol-related behaviors.
  • Gambling: Gambling activates the brain's reward pathways, which play a role in motivation, anticipation, and cravings. Because GLP-1 medications may influence these same pathways, researchers are exploring whether they could help reduce gambling-related urges. Early research is still limited, but the connection is an interesting area of study.
  • Shopping: Compulsive shopping can involve reward-seeking behaviors and difficulty controlling urges. GLP-1 medications are being studied for their potential to influence the brain circuits involved in reward and motivation, raising questions about whether they could eventually help manage compulsive buying behaviors.
  • Sexual behaviors: Certain compulsive sexual behaviors may also involve reward pathways and difficulty regulating urges. Since GLP-1 medications may affect some of these same brain systems, researchers are interested in exploring their potential role.

Although these behaviors are different, they can involve overlapping brain pathways related to reward, motivation, and impulse control. Understanding how GLP-1 medications interact with these systems could help researchers uncover new approaches to managing cravings and compulsive behaviors.

Could GLP-1s Become a New Approach to Addiction Treatment?

It's too early to know. GLP-1 medications are not FDA-approved to treat alcohol use disorder, gambling disorder, compulsive shopping, or other behavioral addictions. They should not replace established treatments, including behavioral therapy and approved medications where appropriate.

At DrWell, we believe understanding emerging research helps patients and providers make informed decisions. GLP-1² is one option within our compounded medication offerings for provider-guided metabolic care. A healthcare provider can help determine whether treatment is appropriate based on individual health needs, medical history, and goals.

Cravings are more complex than willpower alone. As our understanding of the brain's reward system grows, GLP-1 research is opening new avenues for investigation into how these medications may influence behaviors beyond appetite and weight management.

Need help right now?

If you or someone you know is in crisis or thinking about suicide, call or text 988. For free, confidential help finding treatment, call the SAMHSA National Helpline at 1-800-662-4357, available 24 hours a day. In an emergency, call 911.

‍

Featured in this guide

Medications a provider may discuss.

Semaglutide & Tirzepatide

Injection

Compounded semaglutide and tirzepatide combination injection

Learn more →

Listing a medication is not an offer, recommendation, or confirmation of availability. Your provider and pharmacy determine what is appropriate.

Frequently asked questions

What is GLP-1²?

GLP-1² is a a compounded injection that combines semaglutide, a GLP-1 receptor agonist, with tirzepatide, a GIP and GLP-1 receptor agonist. It is prescribed by a licensed provider as part of a medically supervised weight program.

How does GLP-1² work?

Semaglutide mimics a hormone called GLP-1, and tirzepatide mimics GLP-1 and a second hormone called GIP. Both affect appetite and digestion. Because both ingredients act on the GLP-1 pathway, your provider will explain the dose, how it is adjusted over time, and how to inject it.

Can GLP-1 medications help with addictive behaviors?

Researchers are investigating whether GLP-1 medications may influence the brain's reward pathways, which play a role in cravings and compulsive behaviors. Early research, particularly involving alcohol, has shown some promising findings. However, more clinical studies are needed to determine whether these medications can help treat different types of addiction.

How do GLP-1 medications affect the brain's reward system?

GLP-1 receptors are found in areas of the brain involved in motivation, reward, and decision-making. Researchers believe these medications may influence how the brain responds to rewarding experiences, potentially affecting cravings and urges beyond food.

Can semaglutide help reduce alcohol cravings?

Early human studies suggest semaglutide may reduce alcohol cravings and certain measures of alcohol consumption. While these findings are encouraging, larger studies are needed to understand its potential role. Semaglutide is not currently FDA-approved to treat alcohol use disorder.

Are GLP-1 medications being studied for gambling, shopping, or other compulsive behaviors?

Yes. Researchers are interested in whether GLP-1 medications could influence reward-driven behaviors associated with gambling, compulsive shopping, and other conditions. However, human evidence in these areas is currently very limited, and more research is needed.

Could GLP-1² become a treatment for addiction?

It's possible that future research could identify additional applications for GLP-1 medications, but it's too early to know. They are not currently approved to treat behavioral addictions or most substance use disorders. Established treatments, including behavioral therapy and approved medications where appropriate, remain important options.

‍

Keep reading